How is a beyond-use date set for compounded ecnoglutide in sterile water for injection?

The case in front of me: ecnoglutide · sterile water for injection.

I am trying to do this correctly the first time rather than learn it by getting it wrong.

I have already made one mistake here that cost me a vial, so I am being deliberately careful.

What does a defensible version of this look like in practice?

Answering this needs the jurisdiction, since the framework differs substantially between countries and even between states.

Beyond-use dates on compounded sterile preparations are set by standards that depend on the preparation environment and are much shorter than a manufactured product's shelf life.

503A versus 503B

Put another way, additives are the other divergence. Preparations combining an active with vitamins or other agents are not equivalent to the approved product and have not been studied in that combination.

Prohibitions on compounding essential copies of commercially available products are explicit in the relevant regulatory frameworks, with shortage listings as the usual exception.

Nothing here is medical advice.

Ask which salt form. A different salt is a different active moiety.

The underlying point is that salt forms and additives are the usual point of divergence and are worth asking about specifically.

Facility quality varies enormously and is the practical determinant of what you receive. The relevant questions are about sterility assurance, potency testing and beyond-use dating.

Ask for the certificate of analysis on the compounded lot. A serious facility will have one; the request itself is informative.

Compounding is defined in regulation as preparation for an individual patient under prescription and is distinguished from manufacturing by scale and by the patient-specific requirement.

A compounded preparation is unapproved by definition, which is a statement about the framework rather than about the facility.

The framework is jurisdiction-specific. Check yours rather than a general answer.

Start with the regulatory basis, because compounding is permitted under specific conditions and those conditions are the whole subject.

Salt forms matter: a compounded preparation using a different salt from the approved product is not the same active moiety, and that has been the specific object of regulatory warnings.

Regulators generally prohibit compounding what is essentially a copy of a commercially available product, with a shortage listing being the usual exception that permits it temporarily.

Beyond-use dating for compounded sterile preparations is governed by published standards keyed to the compounding environment.

Facility quality is the dominant variable and cannot be assessed from a website.

Compounded means unapproved by definition. That is structural, not pejorative.

edited 8 Mar 2026 by coldbox9 — added the citation requested in comments

The honest answer is that a well-run compounding pharmacy is a serious operation and that the variance across facilities is wide.

A compounded preparation has no marketing authorisation, no batch release by a qualified person and no pharmacovigilance obligation attached to it. That is the structural difference from a licensed product.

The caveat is that the legal and regulatory position differs by jurisdiction and nothing here is legal advice.

Check the beyond-use date and what it was based on.

Copies of commercially available products are generally not permitted, which is the constraint that shapes most of this market.

Compounding is the preparation of a medicine for an individual patient in response to a prescription, where an approved product is unsuitable. It sits outside the approval framework by design rather than by omission.

Ask for the certificate of analysis on the lot. A serious facility has one.